Summit Therapeutics Inc.: Barclays raises target price to $20 from $18
SMMT•Barclays raised its target price for Summit Therapeutics to $20 from $18.
Related News
Liquidia Corporation: BTIG cuts to neutral from buy
LQDA•
Merck schedules third-quarter sales and earnings conference call with investors and analysts
MRK•
Pursuit seeks US Forest Service permit for Glacier View Tram near Glacier National Park
PRSU•
Vulcan Materials Co: Citigroup cuts target price to $300 from $350
VMC•
EM currencies at one-week low as Treasury yields jump; Turkish stocks rebound
SPY•